CVRx, Inc. announced recently that the Centers for Medicare and Medicaid Services (CMS) assigned the company’s Barostim p ...

Akura Medical, a Shifamed portfolio company focused on venous thromboembolism care, announced recently that the FDA has approve ...

A nationwide retrospective study evaluated health care resource utilization and outcomes among patients with ...

Two-year outcomes were reported from the CLOUT registry, which is a prospective, multicenter study evaluating patient ...

Medtronic and Recor Medical, Inc. (and its parent company, Otsuka Medical Devices Co., Ltd.) separately and independently ...

A study assessed the effects of intravascular volume expansion on deep pelvic vein size using the 200-150-125 rule for the ...

Secondary outcomes through 6 months were reported from the VenaSeal Spectrum Surgical Stripping study, a randomized ...

Royal Philips announced enrollment of the first patient in THOR, a United States investigational device exemption (IDE) clinica ...

DEEPER OUS is a prospective, nonrandomized, multicenter, single-arm trial taking place in New Zealand, Germany, and Switzerland ...

The Disrupt PAD BTK II study’s 30-day outcomes were revealed. The core lab–adjudicated, prospective, multicenter, s ...

In the LIFE-BTK trial, several initiatives were implemented to facilitate enrollment of diverse populations, ensuring that pati ...

The final results from the DETOUR2 study evaluated the durability of percutaneous transmural arterial bypass (PTAB) using the D ...